CA2934667A1 - Pyrazolo[1,5-a]pyridine derivatives and methods of their use - Google Patents

Pyrazolo[1,5-a]pyridine derivatives and methods of their use Download PDF

Info

Publication number
CA2934667A1
CA2934667A1 CA2934667A CA2934667A CA2934667A1 CA 2934667 A1 CA2934667 A1 CA 2934667A1 CA 2934667 A CA2934667 A CA 2934667A CA 2934667 A CA2934667 A CA 2934667A CA 2934667 A1 CA2934667 A1 CA 2934667A1
Authority
CA
Canada
Prior art keywords
compound
fluoro
pyrazolo
6alkyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2934667A
Other languages
English (en)
French (fr)
Inventor
Robert L. Hudkins
Allison L. Zulli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ignyta Inc
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of CA2934667A1 publication Critical patent/CA2934667A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2934667A 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use Abandoned CA2934667A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26
US61/920,819 2013-12-26
PCT/US2014/071040 WO2015100117A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Publications (1)

Publication Number Publication Date
CA2934667A1 true CA2934667A1 (en) 2015-07-02

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934667A Abandoned CA2934667A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Country Status (22)

Country Link
US (2) US9914731B2 (enExample)
EP (2) EP3087070B1 (enExample)
JP (1) JP2017500362A (enExample)
KR (1) KR20160110390A (enExample)
CN (1) CN106029661B (enExample)
AU (1) AU2014370186A1 (enExample)
BR (1) BR112016015057A2 (enExample)
CA (1) CA2934667A1 (enExample)
CL (1) CL2016001604A1 (enExample)
DK (1) DK3087070T3 (enExample)
EA (2) EA029757B1 (enExample)
ES (1) ES2654931T3 (enExample)
HU (1) HUE037579T2 (enExample)
IL (1) IL246311A0 (enExample)
MX (1) MX2016008445A (enExample)
NO (1) NO3014707T3 (enExample)
PH (1) PH12016501232A1 (enExample)
PL (1) PL3087070T3 (enExample)
PT (1) PT3087070T (enExample)
SG (1) SG11201605207PA (enExample)
SI (1) SI3087070T1 (enExample)
WO (1) WO2015100117A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210177T1 (hr) * 2015-07-16 2021-03-19 Array Biopharma, Inc. Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
EP3719012B1 (en) * 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
PL3842425T3 (pl) * 2018-08-24 2024-08-19 Transthera Sciences (Nanjing), Inc. Nowy inhibitor będący pochodną chinoliny
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Compound having axl and c-met kinase inhibitory activity, preparation thereof and application thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021197276A1 (en) 2020-03-30 2021-10-07 Hutchison Medipharma Limited Amide compounds and uses thereof
JP7802077B2 (ja) * 2021-07-13 2026-01-19 日本曹達株式会社 ウラシル化合物の製造方法
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l，2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
WO2025034912A2 (en) 2023-08-07 2025-02-13 Cogent Biosciences, Inc. Compounds for fgfr inhibition
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CA2645137A1 (en) * 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
WO2008072634A1 (ja) * 2006-12-12 2008-06-19 Takeda Pharmaceutical Company Limited 縮合複素環化合物
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
US8455477B2 (en) 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
SI2719699T1 (sl) * 2009-12-31 2015-12-31 Hutchison Medipharma Limited Določeni triazolopirazini, njihovi sestavki in načini njihove uporabe
CN103492384B (zh) * 2011-02-25 2016-05-11 诺华股份有限公司 作为trk抑制剂的化合物和组合物
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
US9283225B2 (en) * 2011-08-10 2016-03-15 Merck Patent Gmbh Pyrido-pyrimidine derivatives
WO2013043715A1 (en) * 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
MX342241B (es) * 2011-11-14 2016-09-21 Ignyta Inc Derivados de uracilo como inhibidores de la quinasa axl y c-met.
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
US20180148447A1 (en) 2018-05-31
EA201890061A2 (ru) 2018-05-31
HUE037579T2 (hu) 2018-09-28
ES2654931T3 (es) 2018-02-15
PH12016501232A1 (en) 2016-08-15
DK3087070T3 (en) 2017-12-04
EA201691164A1 (ru) 2016-12-30
EP3087070B1 (en) 2017-11-08
IL246311A0 (en) 2016-08-02
CN106029661B (zh) 2017-11-03
CL2016001604A1 (es) 2017-05-26
CN106029661A (zh) 2016-10-12
EP3087070A1 (en) 2016-11-02
US9914731B2 (en) 2018-03-13
PL3087070T3 (pl) 2018-03-30
NO3014707T3 (enExample) 2018-01-06
SI3087070T1 (en) 2018-01-31
US20160318929A1 (en) 2016-11-03
BR112016015057A2 (pt) 2017-08-08
MX2016008445A (es) 2016-10-28
EA201890061A3 (ru) 2018-09-28
KR20160110390A (ko) 2016-09-21
WO2015100117A1 (en) 2015-07-02
SG11201605207PA (en) 2016-07-28
AU2014370186A2 (en) 2016-07-21
JP2017500362A (ja) 2017-01-05
AU2014370186A1 (en) 2016-07-14
EA029757B1 (ru) 2018-05-31
EP3309160A1 (en) 2018-04-18
PT3087070T (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
EP3087070B1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP5948352B2 (ja) 新規なスルホンアミノキノリン系ヘプシジン拮抗薬
RU2632900C2 (ru) Гетероциклические амины и их применение
JP5789259B2 (ja) 含窒素芳香族複素環誘導体
RU2582610C2 (ru) Производные хинолина и содержащие их ингибиторы melk
CN104302358B (zh) 3‑芳基‑5‑取代的异喹啉‑1‑酮化合物和它们的治疗用途
RU2704129C2 (ru) Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения
HK1217482A1 (en) Enzyme modulators and therapies
AU2015310662C1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
BR112013029508A2 (pt) composto, composição farmacêutica, e, uso do referido composto
JP7086272B2 (ja) イソインドリン－１－オン誘導体、同じものを調製する方法、およびがんを予防するまたは処置するための有効な構成要素として同じものを含む医薬組成物
BRPI0720635A2 (pt) Compostos orgânicos e seus usos
CN104507933A (zh) 氨基喹唑啉和吡啶并嘧啶衍生物
MX2014008647A (es) Compuesto de pirazin-carboxamida.
WO2013100672A1 (ko) 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체
JP2022533710A (ja) Ｎを含むヘテロアリール誘導体およびこれを有効成分として含むがんの予防または治療用薬学的組成物
EP1963315B1 (en) Enzyme inhibitors
AU2016293841B2 (en) Fused quinoline compunds as pi3k/mTor inhibitors
AU2005300734A1 (en) Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
CN114539263A (zh) 一类含氮并杂环化合物及其药用组合物和应用
WO2023006860A1 (en) Srpk inhibitors
HK1184447A (en) Nitrogenated aromatic heterocyclic ring derivative

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171212

FZDE Discontinued

Effective date: 20191218